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Abstract: A novel carbamate prodrug 2 containing a pentagastrin moiety was synthesized. 
2 was designed as a detoxified analogue of the highly cytotoxic natural antibiotic 
duocarmycin SA (1) for the use in a targeted prodrug monotherapy of cancers expressing 
cholecystokinin (CCK-B)/gastrin receptors. The synthesis of prodrug 2 was performed 
using a palladium-catalyzed carbonylation of bromide 6, followed by a radical cyclisation 
to give the pharmacophoric unit 10, coupling of 10 to the DNA-binding subunit 15 and 
transformation of the resulting seco-drug  3b into the carbamate 2 via addition of a 
pentagastrin moiety. 
Keywords: antibiotics, antitumor agents, pentagastrin, prodrug, prodrug monotherapy  
 
1.  Introduction  
One of the major problems in the chemotherapy of cancers is the usually low differentiation 
between normal and malignant cells by the known antiproliferating agents, resulting in severe side 
effects. Several approaches have been developed to overcome this problem like the antibody-directed 
enzyme prodrug therapy (ADEPT) [1,2] and the prodrug monotherapy (PMT) [3].
 Whereas in ADEPT 
artificial antibody-enzyme conjugates are needed for targeting tumor cells, in PMT specific Int. J. Mol. Sci. 2008, 9              
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endogenous enzymes or receptors overexpressed in cancerous tissue are addressed to allow a selective 
killing of tumor cells. In both approaches, a relatively untoxic prodrug is used, which is then 
selectively converted into the corresponding cytotoxic drug in the cancer tissue; however, for PMT the 
prodrug is linked to a ligand which allows a targeting of cancer cells. Among these ligands small 
peptides play an important role having a low immunogenicity as well as high specifities and affinities 
to certain receptors which are overexpressed on certain tumour cells
 [4]. Some of these peptides that 
are already successfully applied in cancer therapy, belong to the gastrin family. For example, 
radiolabeled gastrin derivatives have shown a high therapeutic and diagnostic potential in targeting 
cholecystokinin (CCK-B)/gastrin receptor expressing tumors [5]. In addition, a gastrin derivative was 
linked to a triazene alkylating agent [6]. However, the observed receptor-mediated cytotoxicity of this 
conjugate was quite low. Better results were obtained with heptagastrin linked to an ellipticine 
derivative [7]. A high receptor-mediated cytotoxicity could be achieved with the anthracyclines 
daunorubicin, doxorubicin and 2-pyrrolinodoxorubicin as well as other cytotoxic agents like 
melphalan, cisplatin or methotrexate coupled to peptides of the LHRH [4,8], bombesin [4,8a,9], 
somatostatin [4,8a,10] and neuropeptide Y [4,11] type.
 Recently, we have developed the pentagastrin-
toxin conjugate 3a containing a seco-duocarmycin SA derivative (Scheme 1) [12].  
Scheme 1. (+)-Duocarmycin SA (1), prodrug 2, seco-drugs 3 and drugs 4; a) enzymatic 
toxification of the novel carbamate prodrug 2 to the seco-drug 3b inside the tumor cells 
and b) rapid cyclisation of the seco-drugs 3 in situ to give the cytotoxic drugs 4. 
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Here, we report the synthesis of a novel pentagastrin conjugate 2 for the use in a targeted tumor 
therapy, which has the advantage over normal gastrin-toxin conjugates that a prodrug is used instead 
of a toxic drug (Scheme 1). In this concept, the pentagastrin moiety should serve not only as a 
targeting ligand for CCK-B/gastrin receptors, but also as a detoxifying unit. Thus, the corresponding Int. J. Mol. Sci. 2008, 9              
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drug 4b, which again is an analogue of the naturally occuring antibiotic (+)-duocarmycin SA (1) with 
an IC50 value of 10 pM (L1210) [13], should be formed via 3b inside the tumor cells by cleavage of the 
carbamate by lysosomal enzymes after endocytosis. The antiproliferative effect of 1 and its analogues 
such as the CBI-drugs 4 derive most probably from a selective alkylation of N-3 of adenine in DNA by 
nucleophilic attack at the spirocyclopropyl-cyclohexadienone moiety as the pharmacophoric group 
[14]. Since we have previously shown that the formation of a drug as 4b from a seco-drug as 3b is a 
very fast process and that the blocking of the phenolic hydroxyl group of 3b allows a very strong 
reduction of its cytotoxicity, we used the seco-drug  3b as substrate for the conjugation with the 
pentagastrin moiety, performing the connection to the phenolic hydroxyl group via a carbamate moiety 
[1b,1c,15]. 
In our approach we did not employ the whole heptadecapeptide gastrin but the shorter β-alanine 
modified pentagastrin, because its β-Ala-Trp-Met-Asp-Phe-NH2 sequence representing the C-terminal 
amide of the natural peptides restores the biological activity of gastrin in a comparable order of 
magnitude [4e,16]. As a consequence, the seco-duocarmycin moiety 3b had to be attached via the N-
terminal amino functionality of pentagastrin using a carbamate. Such a carbamate substructure exists 
also in KW-2189 (5) (Figure 1) [17], an agent already investigated in clinical trials, and in several 
other anticancer agents [18]. 
Figure 1. KW-2189 (5). 
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For the formation of the carbamate moiety, we envisaged an addition of an isocyanate to the seco-
drug  3b. The TMSE ester moiety was introduced to allow a better comparison with the already 
prepared pentagastrin-conjugate 3a. Moreover, the handle could be used for the introduction of a 
fluorescence dye to allow an investigation of the mode of action of such a compound employing a 
confocal laser scanning microscope. 
2. Results and Discussion  
2.1. Synthesis 
As starting material for the preparation of 2 we employed the known aminonaphthalin 6 [12].
 6 was 
converted into TMSE ester 7 in 56 % yield by a palladium-catalyzed carbonylation reaction using a 
CO atmosphere (1 bar) and Mo(CO)6 as additional CO source [19] in a mixture of 2-(trimethylsilyl)-
ethanol and DMF (Scheme 2). The moderate yield of 56% of this carbonylation reaction might be due Int. J. Mol. Sci. 2008, 9              
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to the relatively high electron density of 6. Nevertheless, 6 had to be used in the carbonylation reaction 
as the Curtius rearrangement of the corresponding acid to the protected naphtholamine could not be 
achieved after the introduction of the TMSE ester moiety. Iodination of 7 employing NIS [20,21] with 
TsOH·H2O as catalyst followed by N-alkylation of the formed 8  with 1,3-dichloropropene and 
subsequent radical cyclization [22] using the untoxic tris-(trimethylsilyl)-silan (TTMSS) [23] as 
hydride source and AIBN as radical starter provided seco-CBI derivative 10 in 65 % yield over three 
steps. 
Scheme 2. Synthesis of seco-CBI compound 10. a) Mo(CO)6,  1 bar CO,  5 mol% 
Pd(PPh3)2Br2, 20  mol% dppf, nBu3N, TMSEOH, DMF, 120  °C, 7  h, 56%; b) NIS, 
TsOH·H2O, THF/MeOH, 50  °C, 1  h, 73%; c) NaH, 1,3-dichloropropene, DMF, 20  °C, 
13.5 h, 97%; d) HSi(SiMe3)3, AIBN, benzene, reflux, 2 h, 92%. 
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In order to connect 10 with the peptide unit, we used the isocyanate 13 containing an ester moiety. 
This was first reacted with the phenolic hydroxyl group and then bound to the peptide via an amide 
linkage. The required isocyanate 13 was prepared as follows: first, β-alanine (11) was converted into 
the corresponding benzyl ester hydrochloride 12 employing TMSCl and benzylic alcohol [24]. Then, 
the isocyanate moiety was introduced using solid and thus easy to handle triphosgene in refluxing 
toluene to give 13 in 87 % yield over two steps (Scheme 3).  
Scheme 3. Synthesis of isocyanate 13. a) TMSCl, BnOH, 20  °C, 15  h, 89%; b) 
triphosgene, toluene, reflux, 7.5 h, 98%. 
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Hence, the synthesis of carbamate prodrug 2 was completed in seven further steps (Scheme 4). 
After deprotection of the secondary amino functionality in 10 under acidic conditions in an aqueous Int. J. Mol. Sci. 2008, 9              
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HCl/EtOAc mixture with Et3SiH as cation scavenger [25], the obtained hydrochloride salt 14 was 
directly coupled with the DNA-binding subunit TMI-CO2H (15) to give 16 in 43 % yield over two 
steps. Then, the benzyl ether moiety in 16 was cleaved by transfer hydrogenolysis with an aqueous 
ammonium formate solution and palladium on charcoal as the catalyst [26] to yield phenol 3b which 
was subsequently coupled with isocyanate 13 to afford carbamate 17 in a very good yield of 83 % over 
two steps. The benzyl ester in 17 was cleaved again by using transfer hydrogenolytic conditions to 
give 18 in 90 % yield. This reaction had to be carefully monitored by TLC as the carbamate was 
sensitive to these conditions. Finally, carboxylic acid 18 was treated with HOSu/EDC·HCl and the 
resulting active ester 19 directly coupled with the fully unprotected tetrapeptide 20 [27] to yield carba-
mate prodrug 2 in 57 % (83 % based on recovered starting material) over two steps. 
Scheme 4. Synthesis of carbamate prodrug 2. a) HCl/EtOAc, Et3SiH, CH2Cl2, 20 °C, 7 h; 
b) TMI-CO2H (15), EDC·HCl, DMF, 20 °C, 1 d, 43% (two steps); c) Pd/C, NH4HCO2, 
THF/MeOH, 20 °C, 75 min, quant.; d) isocyanate 13, NEt3, CH2Cl2, 0–20 °C, 16 h, 83%; 
e) Pd/C, NH4HCO2, THF/MeOH, 20 °C, 25 min, 90%; f) HOSu, EDC·HCl, THF/CH2Cl2, 
0–20 °C, 15 h; g) tetragastrin (20), NEtiPr2, H2O/DMF, 20 °C, 7 h, 57% (two steps). 
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2.2. In vitro cytotoxicity tests 
 
The in vitro cytotoxicity assays were carried out in duplicate with CCK-B/gastrin-receptor positive 
cells of the human pancreatic cell line MIA PaCa-2 and CCK-B/gastrin-receptor negative cells of the 
human bronchial carcinoma cell line A549 as control in six multiwell plates with concentrations of 
10
2, 10
3 and 10
4 cells per cavity. Incubation with various concentrations of the seco-drug 3b and the 
prodrug 2 was performed in ultraculture medium (Table 1).  
Table 1. In vitro cytotoxicity of prodrug 2 and of seco-drug 3b against CCK-B/gastrin-
receptor positive cells of the human pancreatic cell line MIA PaCa-2 and CCK-B/gastrin-
receptor negative human bronchial carcinoma cells (A549). Cells were exposed to various 
concentrations of the test substance for 24 h at 37 °C; after 10 days of incubation following 
the exposure to the substance, clone formation was compared to an untreated control assay 
and the relative colony-forming rate was determined. IC50 is the drug concentration 
required for 50% growth inhibition of target cells. 
 
Compound 
MIA PaCa-2 
IC50 [nM]  
A549  
IC50 [nM] 
2  0.31 0.11 
3b  0.31 0.14 
 
Prodrug 2 shows the same cytotoxicity as its corresponding seco-drug 3b in the cell culture assays 
using the CCK-B/gastrin-receptor positive cell line (MIA PaCa) and the CCK-B/gastrin-receptor 
negative cell line (A549). Thus, the obtained IC50-values are almost identical in these four 
experiments. This indicates that prodrug 2 seems not to be stable under the used cell culture 
conditions. In fact, HPLC-MS-measurements revealed a decomposition of prodrug 2 under loss of the 
targeting pentagastrin moiety thereby forming the corresponding seco-drug 3b.  
We suppose that the unstability of the carbamate moiety can be traced back to the hydrogen atom at 
its nitrogen which in turn is part of the β-alanine moiety of pentagastrin. We therefore plan to replace 
the hydrogen by a carbon moiety though it is not known whether such a modification of the 
pentagastrin would interfere with the binding of the conjugate to the corresponding CCK-B/gastrin-
receptor. 
3. Experimental Section  
General: All reactions were performed in flame dried glassware under an argon atmosphere. 
Solvents were dried and purified according to standard procedures and redistilled prior to use. TLC 
chromatography was performed on precoated aluminium silica gel SIL G/UV254 plates (Macherey-
Nagel & Co.) and silica gel 60 (0.040-0.063 mm) (Merck) was used for column chromatography. IR: 
Bruker Vector  22.  UV/VIS: Perkin-Elmer Lambda  2. 
1H-NMR:  Varian Mercury-200,  Unity-300 
(300 MHz),  Unity Inova-600 (600  MHz). 
13C-NMR:  Varian Mercury-200  (50 MHz),  Unity-300 
(75 MHz), Unity Inova-600 (150 MHz). For 
1H and 
13C, CDCl3, [D6]DMSO and [D7]DMF were used 
as solvents. Chemical shifts are reported on a δ scale. Signals are quoted as s (singlet), d (doublet), t Int. J. Mol. Sci. 2008, 9              
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(triplet), q (quartet), m (multiplet), mc (centered multiplet) and br (broad). MS: Finnigan MAT 95, 
TSQ 7000, LCQ. HRMS was performed using among others a modified peak matching technique, 
error ±2  ppm, with a resolution of ca. 10,000. Elemental analysis: Mikroanalytisches Labor des 
Institutes für Organische und Biomolekulare Chemie der Universität Göttingen. 
 
3-Amino-1-benzyloxy-N-(tert-butoxycarbonyl)-7-[2-(trimethylsilyl)-ethoxycarbonyl]-naph-
thalene (7): A magnetically stirred and degassed solution of bromide 6 (3.60 g, 8.40 mmol), N(nBu)3 
(6.0 mL, 4.7 g, 25 mmol) and 2-(trimethylsilyl)-ethanol (6.0 mL, 5.0 g, 42 mmol) in DMF (35 mL) was 
treated with Pd(PPh3)2Br2 (332  mg, 420  µmol), 1,1'-bis-(diphenylphosphino)-ferrocene (931  mg, 
1.68 mmol) and Mo(CO)6 (1.1 g, 4.2 mmol). The reaction mixture was degassed again, set under a 
carbon monoxide atmosphere (1 bar) and stirred for 7 h at 120 °C (preheated bath). The alcohol and 
tributylamine were distilled off under reduced pressure, the resulting red oil adsorbed on silica gel and 
subjected to column chromatography (pentane/EtOAc = 10:1 → 7:1) to afford ester 7 (2.32 g, 56 %) as 
orange solid. Rf = 0.43 (pentane/EtOAc = 7:1); 
1H NMR  (300 MHz,  CDCl3):  δ  = 0.08 (s, 9  H, 
Si(CH3)3), 1.13–1.18 (m, 2 H, CH2SiMe3), 1.55 (s, 9 H, C(CH3)3), 4.43–4.49 (m, 2 H, CH2OC=O), 
5.26 (s, 2 H, CH2Ph), 6.73 (brs, 1 H, NH), 7.08 (d, J = 1.5 Hz, 1 H, 2-H), 7.34–7.64 (m, 6 H, 5 × Ph-H, 
4-H), 7.69 (d, J = 8.7 Hz, 1 H, 5-H), 8.02 (dd, J = 8.7, 2.1 Hz, 1 H, 6-H), 8.96 ppm (d, J = 2.1 Hz, 1 H, 
8-H); 
13C NMR (50 MHz, CDCl3): δ = –1.40 (Si(CH3)3), 17.35 (CH2SiMe3), 28.32 (C(CH3)3), 63.09 
(CH2OC=O), 70.30 (CH2Ph), 80.97 (C(CH3)3), 99.48 (C-3), 106.31 (C-1), 121.59, 125.61 (C-4a, C-6), 
125.31, 126.61, 126.87, 127.45, 128.04, 128.61 (C-5, C-7, C-8, 5 × Ph-C), 136.41, 137.13, 138.65 
(C-2, C-8a, Ph-Ci), 152.51, 156.23 (C-4, C=O), 167.11 ppm (C(O)OTMSE); MS (EI, 70 eV): m/z (%) 
= 493 (18) [M]
+, 437 (10) [M – C4H9 + H]
+, 91 (100) [C7H7]
+. 
 
2-Amino-4-benzyloxy-N-(tert-butoxycarbonyl)-1-iodo-6-[2-(trimethylsilyl)-ethoxycarbonyl]-
naphthalene (8): A magnetically stirred solution of 7 (352 mg, 713 µmol) in 1:1 THF/MeOH (10 mL) 
was treated with a solution of TsOH·H2O (14 mg, 71 µmol) in THF (1 mL) and N-iodosuccinimide 
(322 mg, 1.43 mmol). The resulting mixture was warmed to 50 °C and stirred for 1 h. The reaction 
mixture was quenched with NaHCO3 (5 mL, saturated solution) and water and extracted with EtOAc 
(2 × 10 mL). The combined organic phases were washed with Na2S2O3 (1 × 15 mL, saturated solution) 
and brine (15 mL), dried (MgSO4) and concentrated under reduced pressure to give an orange oil. This 
material was adsorbed on silica gel and subjected to column chromatography (pentane/EtOAc = 20:1) 
to afford iodide 8 (320 mg, 73 %) as colorless foam. Rf = 0.65 (pentane/EtOAc = 10:1); 
1H NMR 
(300 MHz, CDCl3): δ = 0.08 (s, 9 H, Si(CH3)3), 1.13–1.18 (m, 2 H, CH2SiMe3), 1.59 (s, 9 H, C(CH3)3), 
4.44–4.49 (m, 2  H, CH2OC=O), 5.31 (s, 2  H, CH2Ph), 7.33–7.60 (m, 5  H, 5  ×  Ph-H), 8.04 (d, 
J = 9.3 Hz, 1 H, 8-H), 8.09 (dd, J = 9.3, 1.8 Hz, 1 H, 7-H), 8.14 (s, 1 H, 3-H), 8.95 ppm (d, J = 1.8 Hz, 
1 H, 5-H); 
13C NMR (50 MHz, CDCl3): δ = –1.40 (Si(CH3)3), 17.34 (CH2SiMe3), 28.30 (C(CH3)3), 
63.29 (CH2OC=O), 70.55 (CH2Ph), 79.16 (C(CH3)3), 81.53 (C-1), 100.13 (C-3), 122.77, 126.27, 
136.16, 137.06 (C-4a, C-6, C-8a, Ph-Ci), 125.62, 127.90, 128.07, 128.16, 128.58, 131.39 (C-5, C-7, 
C-8, 5 × Ph-C), 140.53 (C-2), 152.51, 156.60 (C-4, C=O), 166.66 ppm (C(O)OTMSE); MS (EI, 70 
eV): m/z (%) = 619 (14) [M]
+, 563 (10) [M – C4H9 + H]
+, 535 (18) [M – C4H8 – CO]
+, 491 (5) [M – I – 
H]
+, 91 (100) [C7H7]
+, 57 (36) [C4H9]
+. 
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(E/Z)-2-Amino-4-benzyloxy-N-(tert-butoxycarbonyl)-N-(3-chloro-2-propenyl)-1-iodo-6-[2-
(trimethylsilyl)-ethoxycarbonyl]-naphthalene (9): A magnetically stirred solution of 8 (54  mg, 
87 µmol) in DMF (1.5 mL) was treated with NaH (5.20 mg, 60 % in oil, 218 µmol). Stirring was 
continued for 40 min at 20 °C before (E/Z)-1,3-dichloropropene (16.0 μL, 19.0 mg, 174 µmol) was 
added dropwise, and it was stirred for a further 13 h at 20 °C. The ensuing mixture was then adjusted 
to pH 5 with NH4Cl (saturated solution) and extracted with EtOAc (4 × 5 mL). The combined organic 
phases were washed with water (10  mL), brine (10  mL), dried (MgSO4) and concentrated under 
reduced pressure to give an orange oil. Subjection of this material to column chromatography 
(pentane/EtOAc = 10:1)  gave  iodide  9 (59  mg, 97  %) as pale yellow foam. Rf = 0.43, 0.52 
(pentane/EtOAc = 10:1); 
1H NMR (200 MHz, CDCl3): δ = –0.14/0.10 (2 × s, 9 H, Si(CH3)3), 1.14–
1.22 (m, 2 H, CH2SiMe3) 1.30/1.58 (2 × s, 9 H, C(CH3)3), 3.78 (dd, J = 13.8, 6.4 Hz, 1 H, 1'-Ha), 4.19–
4.35 (m, 1 H, 1'-Hb), 4.46–4.54 (m, 2 H, CH2OC=O), 5.31 (brs, 2 H, CH2Ph), 5.92–6.15 (m, 2 H, 2'-H, 
3'-H), 6.65–6.85 (m, 1 H, 3-H), 7.30–7.55 (m, 5 H, 5 × Ph-H), 8.15 (d, J = 8.0 Hz, 1 H, 8-H), 8.25 (d, 
J = 8.0  Hz, 1  H, 7-H), 9.01–9.10 ppm (m, 1  H, 5-H); 
13C NMR  (50 MHz,  CDCl3):  δ =  –1.40 
(Si(CH3)3), 17.33 (CH2SiMe3), 28.19/28.46 (C(CH3)3), 45.76/48.97 (C-1'), 63.53/64.59 (CH2OC=O), 
70.49/70.58 (CH2Ph), 80.88/81.39 (C(CH3)3), 94.52 (C-1), 107.93/108.51 (C-3), 120.87/121.96 (C-3'), 
124.79, 128.26/128.29, 135.91/136.01, 137.51/137.64 (C-4a, C-6, C-8a, Ph-Ci), 125.36, 
127.00/127.20, 127.90/127.94, 128.17/128.21, 128.45, 128.72/128.76, 133.06 (C-5, C-7, C-8, C-2', 
5  ×  Ph-C), 144.60/144.98 (C-2), 153.37/153.59 (C-4), 155.99/156.12 (C=O), 166.40/166.43 ppm 
(C(O)OTMSE); MS (EI, 70 eV): m/z (%) = 694 (16) [M + H]
+, 566 (18) [M – I]
+, 510 (88) [M – I – 
C4H9 + H]
+, 91 (100) [C7H7]
+, 57 (16) [C4H9]
+. 
 
(1R/S)-5-Benzyloxy-3-(tert-butoxycarbonyl)-1-chloromethyl-2,3-dihydro-1H-benz[e]indole-7-
carboxylic acid [2-(trimethylsilyl)-ethyl] ester (10): Through a magnetically stirred solution of 
iodide 9 (308 mg, 444 μmol) in benzene (13 mL) was bubbled argon for 45 min. The oxygen-free 
solution was then treated with tris-(trimethylsilyl)-silane (124  μL, 99.0  mg, 400  μmol) and AIBN 
(17.0 mg, 102 μmol) and stirred for 2 h under reflux. The ensuing mixture was adsorbed on silica gel 
and subjected to column chromatography (pentane/EtOAc = 10:1) to afford 10 (208 mg, 92 %) as pale 
yellow solid. Rf = 0.44 (pentane/EtOAc = 10:1); UV/VIS (CH3CN): λmax (lg ε) = 217 (4.417), 271 
(4.753), 354 nm (4.158); IR (KBr): ν ~ = 3388 (NH), 2955, 1700 (C=O), 1621, 1461, 1412, 1366, 1249, 
1139, 928, 839 cm
–1; 
1H NMR (300 MHz, CDCl3): δ = 0.08 (s, 9 H, Si(CH3)3), 1.12–1.18 (m, 2 H, 
CH2SiMe3), 1.61 (s, 9 H, C(CH3)3), 3.45 (t, J = 10.5 Hz, 1 H, 10-Hb), 3.88–4.02 (m, 2 H, 1-H, 10-Ha), 
4.14 (dd, J = 11.4, 9.0  Hz, 1  H, 2-Hb), 4.27 (d, J = 11.4  Hz, 1  H, 2-Ha), ), 4.44–4.49 (m, 2  H, 
CH2OC=O), 5.29 (s, 2 H, CH2Ph), 7.35–7.48 (m, 3 H, 3 × Ph-H), 7.54–7.59 (m, 2 H, 2 × Ph-H), 7.64 
(d, J = 8.7 Hz, 1 H, 9-H), 7.87 (brs, 1 H, 4-H), 8.08 (dd, J = 8.7, 1.5 Hz, 1 H, 8-H), 9.02 ppm (d, J = 
1.5 Hz,  1 H,  6-H); 
13C NMR  (125 MHz,  CDCl3):  δ  = –1.41 (Si(CH3)3), 17.33 (CH2SiMe3), 28.41 
(C(CH3)3), 41.38 (C-1), 46.36 (C-10), 53.11 (C-2), 63.14 (CH2OC=O), 70.42 (CH2Ph), 81.43 
(C(CH3)3), 96.93 (C-4), 114.37, 121.50, 124.92, 132.37, 144.14 (C-3a, C-5a, C-7, C-9a, C-9b), 121.72 
(C-9), 126.75 (C-6), 127.21 (C-8), 127.62, 128.07, 128.59 (5 × Ph-C), 136.34 (Ph-Ci), 152.41 (C-5), 
157.25 (C=O), 166.91 ppm (C(O)OTMSE); MS (EI, 70 eV): m/z (%) = 567 (4) [M]
+, 511 (7) [M – 
C4H9 + H]
+, 91 (90) [C7H7]
+, 57 (30) [C4H9]
+; HRMS: calcd for C31H38ClNO5Si: 567.2208; confirmed. 
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β-Alanine benzyl ester hydrochloride (12): A magnetically stirred suspension of β-alanine (11) 
(1.00 g, 11.2 mmol) in benzylic alcohol (56.0 mL, 58.0 g, 539 mmol) was treated dropwise over a 
period of 10 min with trimethylsilylchloride (3.6 mL, 3.0 g, 28 mmol) and stirring continued for a 
further 15 h at 20 °C. The resulting clear solution was poured into Et2O (600 mL), the precipitate 
collected by filtration and washed with Et2O (100 mL). Drying of this material under reduced pressure 
gave hydrochloride 12 (2.15 g, 89 %) as white solid; 
1H NMR (200 MHz, [D6]DMSO): δ = 2.79 (t, J = 
7.0 Hz, 2 H, 2-H2), 3.03 (t, J = 7.0 Hz, 2 H, 3-H2), 5.13 (s, 2 H, CH2Ph), 7.32–7.41 (m, 5 H, 5 × Ph-H), 
8.23 ppm (brs, 3 H, NH3
+); 
13C NMR (50 MHz, [D6]DMSO): δ = 31.34 (C-2), 34.47 (C-3), 65.87 
(CH2Ph), 127.95 (2 × Ph-C), 128.01 (Ph-Cp), 128.34 (2 × Ph-C), 135.73 (Ph-Ci), 170.05 ppm (C=O); 
MS (ESI): m/z (%) = 180 (100) [M – Cl]
+, 359 (100) [2M – Cl – HCl]
+. 
 
3-Isocyano-propionic acid benzyl ester (13): A magnetically stirred suspension of hydrochloride 
12 (2.13  g, 9.88  mmol) in toluene (15  mL) was treated with triphosgene (2.93  g, 9.88  mmol) and 
heated to reflux for 7.5  h (end of HCl-evolution). The resulting solution was concentrated under 
reduced pressure to afford isocyanate 13 (1.99 g, 98 %) as yellow liquid which was used for the next 
reaction without further purification. Rf = 0.21 (pentane/EtOAc = 10:1); IR (film): ν ~ = 3349, 2957, 
2277 (NCO), 1736 (C=O), 1498, 1176, 823, 752, 699 cm
–1; 
1H NMR (200 MHz, CDCl3): δ = 2.65 (t, 
J = 6.4 Hz, 2 H, 2-H2), 3.61 (t, J = 6.4 Hz, 2 H, 3-H2), 5.18 (s, 2 H, CH2Ph), 7.35–7.40 ppm (m, 5 H, 
5 × Ph-H). 
 
(1R/S)-5-Benzyloxy-1-chloromethyl-3-(5,6,7-trimethoxyindole-2-carbonyl)-2,3-dihydro-1H-
benz[e]indole-7-carboxylic acid [2-(trimethylsilyl)-ethyl] ester (16): A solution of the protected 
amine 10 (369 mg, 650 μmol) in CH2Cl2 (5 mL) was treated with HCl (18 mL of a 4 M solution in 
EtOAc) and Et3SiH (105 μL, 76.0 mg, 650 μmol) and stirred for 7 h at 20 °C. The solvent was removed 
under reduced pressure and the ensuing residue treated with toluene (2  ×  10  mL) and again 
concentrated under reduced pressure. The resulting crude hydrochloride 14 was dried under reduced 
pressure and then treated with 5,6,7-trimethoxyindole-2-carboxylic acid (15) (180  mg, 715  μmol), 
EDC·HCl (374 mg, 1.95 mmol) and DMF (16 mL) and stirred for 1 d at 20 °C. The reaction mixture 
was adjusted to pH 2 with HCl (2 N) and extracted with EtOAc (4 × 20 mL). The combined organic 
phases were washed with water (3 × 20 mL), brine (20 mL), dried (MgSO4) and concentrated under 
reduced pressure to give a brown solid. This material was adsorbed on silica gel and subjected to 
column chromatography (pentane/EtOAc = 3:1) to yield 16 (196 mg, 43 % over two steps) as green 
solid. Rf = 0.57 (pentane/ EtOAc = 2:1); UV/VIS (CH3CN): λmax (lg ε) = 209 (4.758), 271 (4.470), 315 
(4.465), 363 nm (4.524); IR (KBr): ν ~ = 3461 (NH), 2951, 1711 (C=O), 1624, 1527, 1459, 1408, 1309, 
1107, 837, 747 cm
–1; 
1H NMR (300 MHz, CDCl3): δ = 0.09 (s, 9 H, Si(CH3)3), 1.13–1.19 (m, 2 H, 
CH2SiMe3), 3.42 (dd, J = 10.8, 10.2 Hz, 1 H, 10-Hb), 3.90–4.05 (m, 11 H, 3 × OCH3, 1-H, 10-Ha), 
4.43–4.48 (m, 2 H, CH2OC=O), 4.56 (dd, J = 11.1, 8.7 Hz, 1 H, 2-Hb), 4.71 (dd, J = 11.1, 1.8 Hz, 1 H, 
2-Ha), 5.25–5.31 (m, 2 H, CH2Ph), 6.85 (s, 1 H, 4'-H), 6.96 (d, J = 2.4 Hz, 1 H, 3'-H), 7.31–7.55 (m, 
5 H, 5 × Ph-H), 7.62 (d, J = 9.0 Hz, 1 H, 9-H), 8.07 (dd, J = 9.0, 1.8 Hz, 1 H, 8-H), 8.21 (s, 1 H, 4-H), 
9.03 (d, J = 1.8 Hz, 1 H, 6-H), 9.75 ppm (d, J = 2.4 Hz, 1 H, indole-NH); 
13C NMR (75 MHz, CDCl3): 
δ = –1.47 (Si(CH3)3), 17.26 (CH2SiMe3), 42.72 (C-1), 45.88 (C-10), 55.11 (C-2), 56.11, 61.00, 61.36 
(3 × OCH3), 63.18 (CH2OC=O), 70.30 (CH2Ph), 97.54 (C-4'), 98.87 (C-4), 106.75 (C-3'), 115.94, Int. J. Mol. Sci. 2008, 9              
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123.45, 125.65, 131.71, 144.30 (C-3a, C-5a, C-7, C-9a, C-9b), 121.99 (C-9), 122.48, 125.61, 129.48, 
138.72, 140.55 (C-2', C-3a', C-6', C-7', C-7a'), 126.47 (C-6), 127.12 (C-8), 127.44, 127.97, 128.49 
(5 × Ph-C), 136.22 (Ph-Ci), 150.08 (C-5'), 156.65 (C-5), 160.51 (C=O), 166.62 ppm (C(O)OTMSE); 
MS (ESI): m/z (%) = 723 (100) [M + Na]
+, 1423 (75) [2M + Na]
+, 699 (100) [M – H]
–; HRMS: calcd 
for C38H41ClN2O7Si: 701.2444 [M + H]
+; found: 701.2441. 
 
(1R/S)-1-Chloromethyl-5-hydroxy-3-(5,6,7-trimethoxyindole-2-carbonyl)-2,3-dihydro-1H-
benz[e]indole-7-carboxylic acid [2-(trimethylsilyl)-ethyl] ester (3b): A magnetically stirred solution 
of benzyl ether 16 (152 mg, 217 μmol) in 3:1 THF/MeOH (6 mL) was treated with 10 % Pd/C (62 mg) 
and dropwise with NH4HCO2 (572 μL of a 25 % solution in water, 2.26 mmol) and stirring continued 
for 75 min at 20 °C. The reaction mixture was filtered through a pad of Celite
® and it was thoroughly 
washed with MeOH and THF. The filtrate was dried (MgSO4) and concentrated under reduced 
pressure to give 3b (133 mg, quant.) as yellow solid which was used for the next reaction without 
further purification. Rf = 0.25 (pentane/ EtOAc = 2:1); 
1H NMR (300 MHz, [D6]DMSO): δ = 0.09 (s, 
9 H, Si(CH3)3), 1.12–1.17 (m, 2 H, CH2SiMe3), 3.81–3.88 (m, 7 H, 2 × OCH3, 10-Hb), 3.95 (s, 3 H, 
OCH3), 4.02 (dd, J = 11.1, 3.1 Hz, 1 H, 10-Ha), 4.20 (mc, 1 H, 1-H), 4.41–4.50 (m, 3 H, CH2OC=O, 
2-Hb), 4.74 (dd, J = 11.1, 9.1 Hz, 1 H, 2-Ha), 6.97 (s, 1 H, 4'-H), 7.07 (d, J = 2.0 Hz, 1 H, 3'-H), 7.91–
7.98 (m, 3 H, 4-H, 8-H, 9-H), 8.82 (d, J = 1.0 Hz, 1 H, 6-H), 10.83 (s, 1 H, OH), 11.42 ppm (d, J = 
2.0 Hz, 1 H, indole-NH); 
13C NMR (75 MHz, [D6]DMSO): δ = –1.45 (Si(CH3)3), 16.87 (CH2SiMe3), 
40.72 (C-1), 47.36 (C-10), 55.09 (C-2), 55.93, 60.84, 61.00 (3 × OCH3), 62.56 (CH2OC=O), 98.07 
(C-4'), 100.82 (C-4), 106.31 (C-3'), 115.12, 123.06, 125.45, 131.92, 144.76 (C-3a, C-5a, C-7, C-9a, 
C-9b), 120.95, 123.12, 130.69, 139.00, 139.94 (C-2', C-3a', C-6', C-7', C-7a'), 123.94 (C-9), 125.89 
(C-8), 126.02 (C-6), 149.19 (C-5'), 155.57 (C-5), 160.39 (C=OTMI), 165.89 ppm (C(O)OTMSE); MS 
(ESI): m/z (%) = 633 (100) [M + Na]
+, 1243 (29) [2M + Na]
+, 573 (100) [M – H – HCl]
–, 609 (22) [M 
– H]
–; HRMS: calcd for C31H35ClN2O7Si: 611.1975 [M + H]
+; found: 611.1975. 
 
(1R/S)-5-(2-Benzyloxycarbonyl-ethylcarbamoyloxy)-1-chloromethyl-3-(5,6,7-trimethoxyindo-
le-2-carbonyl)-2,3-dihydro-1H-benz[e]indole-7-carboxylic acid [2-(trimethylsilyl)-ethyl] ester 
(17): A magnetically stirred solution of phenol 3b (198 μmol, 121 mg) in CH2Cl2 (15 mL) at 0 °C was 
treated dropwise with 13 (203  μL, 203  mg; 990  μmol) and then triethylamine (139  μL, 100  mg, 
990 μmol). The reaction mixture was warmed to 20 °C and stirred for a further 16 h. The ensuing 
solution was cooled to 0 °C, adjusted to pH 2 with HCl (2 N) and extracted with EtOAc (4 × 10 mL). 
The combined organic phases were washed with brine (10 mL), dried (MgSO4) and concentrated under 
reduced pressure to give a yellow solid. This material was adsorbed on silica gel and subjected to 
column chromatography (pentane/EtOAc  =  1:1) to afford carbamate 17 (135  mg, 83  %) as yellow 
solid. Rf = 0.29 (pentane/EtOAc = 2:1); 
1H NMR (300 MHz, [D6]DMSO, 100 °C): δ = 0.10 (s, 9 H, 
Si(CH3)3), 1.13–1.19 (m, 2 H, CH2SiMe3), 2.71 (t, J = 7.1 Hz, 2 H, 2''-H2), 3.47–3.53 (m, 2 H, 1''-H2), 
3.85 (s, 6 H, 2 × OCH3), 3.98 (dd, J = 11.2, 6.8 Hz, 1 H, 10-Hb), 4.00 (s, 3 H, OCH3), 4.09 (dd, J = 
11.2, 3.4 Hz, 1 H, 10-Ha), 4.39 (mc, 1 H, 1-H), 4.45–4.50 (m, 2 H, CH2OC=O), 4.58 (dd, J = 11.1, 
2.6 Hz, 1 H, 2-Hb), 4.80 (dd, J = 11.1, 9.2 Hz, 1 H, 2-Ha), 5.17 (s, 2 H, CH2Ph), 6.99 (s, 1 H, 4'-H), 
7.09 (d, J = 2.2 Hz, 1 H, 3'-H), 7.30–7.41 (m, 5 H, 5 × Ph-H), 8.04 (dd, J = 8.7, 1.4 Hz, 1 H, 8-H), 8.09 
(d, J = 8.7 Hz, 1 H, 9-H), 8.24 (s, 1 H, 4-H), 8.62 (d, J = 1.4 Hz, 1 H, 6-H), 11.02 ppm (brs, 1 H, Int. J. Mol. Sci. 2008, 9              
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indole-NH); 
13C NMR  (75 MHz,  [D6]DMSO, 100  °C): δ  = –0.95 (Si(CH3)3), 17.61 (CH2SiMe3), 
34.62/34.68 (C-2''), 37.58/37.60 (C-1''), 41.76 (C-1), 47.79/47.84 (C-10), 55.62 (C-2), 56.99 (OCH3), 
61.38  (2 × OCH3), 63.36 (CH2OC=O), 66.15 (CH2Ph), 99.48 (C-4'), 107.05 (C-3'), 111.34 (C-4), 
122.42, 124.17, 126.73, 132.19, 144.43 (C-3a, C-5a, C-7, C-9a, C-9b), 123.78, 126.36, 131.09, 139.56, 
140.95 (C-2', C-3a', C-6', C-7', C-7a'), 124.29 (C-9), 125.41 (C-6), 126.78 (C-8), 128.23 (2 × Ph-C), 
128.35 (Ph-Cp), 128.81 (2 × Ph-C), 136.72 (Ph-Ci), 149.15 (C-5'), 150.13 (OC(O)N), 156.16/1546.18 
(C-5), 161.23 (C=OTMI), 166.19 (C(O)OTMSE), 171.23 ppm (C(O)OBn); MS (ESI): m/z (%) = 611 
(100) [M – C(O)NH-β-Ala-OBn + H]
+, 838 (18) [M + Na]
+, 1653 (14) [2M + Na]
+, 573 (100) [M – 
C(O)NH-β-Ala-OBn – HCl]
–, 609 (55) [M – C(O)NH-β-Ala-OBn – H]
–. 
 
(1R/S)-5-(2-Carboxy-ethylcarbamoyloxy)-1-chloromethyl-3-(5,6,7-trimethoxyindole-2-carbo-
nyl)-2,3-dihydro-1H-benz[e]indole-7-carboxylic acid [2-(trimethylsilyl)-ethyl] ester (18): A 
magnetically stirred solution of benzyl ester 17 (203 mg, 249 μmol) in 3:1 THF/MeOH (10 mL) was 
treated with 10 % Pd/C (83 mg) and dropwise with NH4HCO2 (653 μL of a 25 % solution in water, 
2.59 mmol). Stirring was continued for 25 min (TLC-monitoring necessary as the alanyl residue is 
easily cleaved off) at 20 °C. The reaction mixture was filtered through a pad of Celite
®, which was 
thoroughly washed with MeOH and CH2Cl2. The combined filtrates were concentrated under reduced 
pressure, the residue dissolved in CH2Cl2, dried (MgSO4) and concentrated under reduced pressure 
again to give a yellow oil. This material was adsorbed on silica gel and subjected to column 
chromatography (CH2Cl2/ MeOH = 20:1) to afford acid 18 (163 mg, 90 %) as pale yellow solid. Rf = 
0.44 (CH2Cl2/MeOH = 10:1); 
1H NMR (300 MHz, CDCl3): δ = 0.06 (s, 9 H, Si(CH3)3), 1.12 (mc, 2 H, 
CH2SiMe3), 2.74 (mc, 2 H, 2''-H2), 3.41 (mc, 1 H, 10-Hb), 3.65 (mc, 2 H, 1''-H2), 3.83–4.07 (m, 11 H, 
1-H, 10-Ha, 3 × OCH3), 4.42 (mc, 2 H, CH2OC=O), 4.57–4.64 (m, 1 H, 2-Hb), 4.71–4.74 (m, 1 H, 
2-Ha), 6.39 (brs, 1 H, NH), 6.87 (brs, 1 H, 4'-H), 6.99 (brs, 1 H, 3'-H), 7.62 (mc, 1 H, 9-H), 8.01 (mc, 
1  H, 8-H), 8.41 (brs, 1  H, 4-H), 8.56 (brs, 1  H, 6-H), 9.99 ppm (brs, 1  H, indole-NH); 
13C NMR 
(75 MHz, CDCl3): δ = –1.46 (Si(CH3)3), 17.34 (CH2SiMe3), 34.17 (C-2''), 36.99 (C-1''), 43.01 (C-1), 
45.75 (C-10), 55.17 (C-2), 56.22, 61.31, 61.49 (3 × OCH3), 63.65 (CH2OC=O), 97.78 (C-4'), 107.11 
(C-3'), 111.78 (C-4), 121.31, 124.21, 126.85, 131.42, 143.39 (C-3a, C-5a, C-7, C-9a, C-9b), 122.50 
(C-9), 123.56, 125.86, 129.29, 138.68, 140.83 (C-2', C-3a', C-6', C-7', C-7a'), 125.93 (C-6), 126.52 
(C-8), 149.00 (C-5'), 150.10 (OC(O)N), 154.39 (C-5), 160.58 (C=OTMI), 166.61 (C(O)OTMSE), 
171.50 ppm (C(O)OH); MS (ESI): m/z (%) = 748 (90) [M + Na]
+, 1473 (100) [2M + Na]
+, 573 (96) [M 
– C(O)NH-β-Ala-OH – HCl]
–, 1449 (100) [2M – H]
–. 
 
(1R/S)-1-Chloromethyl-5-[2-(N-succinimidyloxycarbonyl)-ethyl-carbamoyloxy]-3-(5,6,7-tri-
methoxyindole-2-carbonyl)-2,3-dihydro-1H-benz[e]indole-7-carboxylic acid [2-(trimethylsilyl)-
ethyl] ester (19): A magnetically stirred solution of acid 18 (110  mg, 152  μmol) and 
N-hydroxysuccinimide (26.0  mg, 228  μmol) in 1:1 THF/CH2Cl2 (10  mL) at 0  °C was treated with 
EDC·HCl (44.0 mg, 228 μmol). The reaction mixture was warmed to 20 °C and stirring continued for 
15  h. The ensuing solution was then adjusted to pH  2 with HCl (2  N) and extracted with EtOAc 
(4 × 10 mL). The combined organic phases were washed with brine (10  mL), dried (MgSO4) and 
concentrated under reduced pressure to afford 19 as yellow solid which was used for the next reaction Int. J. Mol. Sci. 2008, 9              
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without further purification. Rf = 0.83 (CH2Cl2/MeOH = 10:1); MS (ESI): m/z (%) = 845 (90) [M + 
Na]
+, 1667 (100) [2M + Na]
+, 573 (100) [M – C(O)NH-β-Ala-OSu – HCl]
–. 
 
(1R/S)-1-Chloromethyl-5-(L-phenylalaninamidyl-L-aspartyl-L-methionyl-L-tryptophyl-β-
alanyl-carbonyloxy)-3-(5,6,7-trimethoxyindole-2-carbonyl)-2,3-dihydro-1H-benz[e]indole-7-car-
boxylic acid [2-(trimethylsilyl)-ethyl] ester (2): A magnetically stirred solution of tetragastrin (20)
[27] 
(39.4 mg, 66.0 μmol) in water (1 mL) was treated with NEtiPr2 (11.5 μL, 8.50 mg, 66.0 μmol) and 
dropwise with a solution of crude 19 (49 mg, 60 μmol) in DMF (3.5 mL). Stirring was continued for 
7 h at 20 °C. The ensuing mixture was adjusted to pH 2 with HCl (2 N) and extracted with EtOAc 
(5 × 5 mL). The combined organic phases were washed with water (5 mL) and brine (5 mL), treated 
with toluene (5 mL) and concentrated under reduced pressure. The resulting yellow solid was adsorbed 
on silica gel and subjected to column chromatography (CH2Cl2/MeOH = 15:1 + 0.5 % HOAc → 10:1 
+ 0.5 % HOAc) to give 2 (45 mg, 57 % over two steps, 83 % based on recovery, 1:1 mixture of both 
diastereomeres) as light yellow solid. Further purification was achieved by HPLC. Rf = 0.27 
(CH2Cl2/MeOH = 10:1 + 0.5 % HOAc); 
1H NMR (600 MHz, [D7]DMF): δ = 0.10/0.12 (2 × s, 9 H, 
Si(CH3)3), 1.20 (mc, 2 H, CH2SiMe3), 1.98–2.07 (m, 5 H, 2c-H2, SCH3), 2.37–2.66 (m, 6 H, 2b-H2, 
3c-H2, 1e-H2), 2.98–3.06 (m, 3 H, 2a-Hb, 1f-H2), 3.17 (dd, J = 14.8, 8.4 Hz, 1 H, 2d-Hb), 3.21–3.24 (m, 
1 H, 2a-Ha), 3.28–3.33 (m, 1 H, 2d-Ha), 3.88 (s, 3 H, OCH3), 3.90 (s, 3 H, OCH3), 3.95 (dd, J = 11.1, 
7.9 Hz, 1 H, 10-Hb), 4.03 (s, 3 H, OCH3), 4.12 (dd, J = 11.1, 3.3 Hz, 1 H, 10-Ha), 4.30 (mc, 1 H, 1-H), 
4.42–4.47 (m, 1 H, 1c-H), 4.50 (mc, 2 H, CH2OC=O), 4.58 (mc, 1 H, 1a-H), 4.64 (mc, 1 H, 1b-H), 4.67 
(dd, J = 10.7, 2.2 Hz, 1 H, 2-Hb), 4.73 (mc, 1 H, 1d-H), 4.85 (dd, J = 10.7, 9.1 Hz, 1 H, 2-Ha), 6.57 (s, 
1 H, NH), 6.97 (mc, 1 H, 5d'-H), 7.05 (s, 1 H, 4'-H), 7.06 (mc, 1 H, 6d'-H), 7.17 (mc, 1 H, 1 × Ph-H), 
7.19 (mc, 2 H, 3'-H, 2d'-H), 7.24–7.32 (m, 4 H, 4 × Ph-H), 7.37/7.39 (2 × d, J = 8.0 Hz, 1 H, 7d'-H), 
7.57/7.63 (2 × d, J = 7.9 Hz, 1 H, 4d'-H), 7.73 (brs, 1 H, NH), 7.83 (brs, 1 H, NH), 8.02 (d, J = 8.8 Hz, 
1 H, 9-H), 8.05 (dd, J = 8.8, 1.6 Hz, 1 H, 8-H), 8.11 (brs, 1 H, 4-H), 8.18–8.44 (m, 4 H, NH), 8.99 (d, 
J = 1.6  Hz, 1  H, 6-H), 10.82/10.87 (2  ×  s, 1  H, indole-NHTrp), 11.34 ppm (s, 1  H, indole-NHTMI); 
13C NMR (150 MHz, [D7]DMF): δ = –1.46/–1.42 (Si(CH3)3), 15.01 (SCH3), 17.67/17.76 (CH2SiMe3), 
28.12 (C-2d), 30.79 (C-3c), 31.88 (C-2c), 32.09 (C-1e), 35.02 (C-1f), 38.16 (C-2a), 39.40 (C-2b), 
42.21 (C-1), 47.94 (C-10), 51.56 (C-1b), 53.65 (C-1c), 55.07 (C-1d), 55.27 (C-1a), 56.03 (C-2), 
56.46/56.49, 61.36, 61.43 (3 × OCH3), 63.38 (CH2OC=O), 98.89 (C-4'), 101.95 (C-4), 107.19 (C-3'), 
110.62 (C-3d'), 111.93 (C-7d'), 116.06, 124.35, 126.61, 131.78, 145.99 (C-3a, C-5a, C-7, C-9a, C-9b), 
118.89 (C-5d'), 118.95 (C-4d'), 121.46/121.51 (C-6d'), 122.17, 129.86, 133.05, 139.97, 141.16 (C-2', 
C-3a', C-6', C-7', C-7a'), 123.75 (C-9), 124.41 (C-2d'), 126.85, 126.91 (C-6, C-8, Ph-Cp), 128.51 
(C-3ad'), 128.78 (2 × Ph-C), 129.83 (2 × Ph-C), 137.33 (C-7ad'), 139.04 (Ph-Ci), 150.54 (C-5'), 152.52 
(OC(O)N), 156.90 (C-5), 161.36 (C=OTMI), 162.20 (C=OAla), 166.96 (C(O)OTMSE), 170.71, 171.25, 
172.27, 172.33 (4 × C=O), 184.62 ppm (C(O)OH); MS (ESI): m/z (%) = 633 (100) [M – C(O)NH-
pentapeptide + H + Na]
+, 573 (100) [M  –  C(O)NH-pentapeptide – Cl]
–; HRMS: calcd for 
C64H74ClN9O15SSi: 1304.4556 [M + H]
+; found: 1304.4558; HPLC (preparative): column: Kromasil 
100 C18; eluent: 85 % MeOH, 15 % H2O + 0.05 % TFA; flow: 12 mL/min; Rt: 31–40 min. 
 
Cell culture: Human bronchial carcinoma cells of line A549 (ATCC CCL 185) were kindly 
provided by the Institut für Zellbiologie, Universität Essen, and human pancreatic carcinoma cells Mia Int. J. Mol. Sci. 2008, 9              
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PaCa-2 by the Universitätsklinikum Göttingen, Abteilung Hämatologie und Onkologie. Cell lines were 
maintained as exponentially growing cultures at 37  °C and 7.5% CO2 in air in culture medium 
(DMEM (Biochrom) supplemented with 10 % fetal calf serum, 44 mM NaHCO3 (Biochrom) and 4 mM 
L-Glutamine (Invitrogen)).  
 
In vitro cytotoxicity assays: Cells of line A549 or MIA PaCa-2 were seeded in duplicates in 6 
multiwell plates at concentrations of 10
2, 10
3 and 10
4 cells per well. After cells were allowed to 
adhear, cells were washed in a serum-free incubation medium (Ultraculture medium, Lonza). 
Incubation with compounds 2 and 3b was then performed in Ultraculture medium at various 
concentrations for 24 h. All substances were used as freshly prepared solutions in DMSO (Merck) 
diluted with incubation medium to a final concentration of DMSO of 1% in the wells. After exposure 
the test substance was removed and cells were washed with fresh medium. Cultivation in normal 
growth medium was done for 10 days. The medium was removed, the clones were dried and stained 
with Löffler’s methylene blue (Merck) and then counted macroscopically. 
The IC50 values are based on the relative colony-forming rate, which was determined according to 
the following formula: relative colony-forming rate [%] = 100 × (number of clones counted after 
exposure) / (number of clones counted in the control). 
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